UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

**Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): November 10, 2010

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	000-32085	36-4392754
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

222 Merchandise Mart Plaza, Suite 2024, Chicago, Illinois 60654
(Address of Principal Executive Offices) (Zip Code)

Registrant's Telephone Number, Including Area Code: (312) 506-1200

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

Attached as Exhibit 99.1 hereto is an Investor Presentation dated November 2010, which is incorporated herein by reference.

The information contained in, or incorporated into, this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

Please refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

Item 9.01 Financial Statements, *Pro Forma* Financial Information and Exhibits.

(d) Exhibits.

Exhibit No.	
Exhibit 99.1	Investor Presentation dated November 2010

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

Date: Novmber 10, 2010

By: /s/ WILLIAM J. DAVIS

William J. Davis
Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	
Exhibit 99.1	Investor Presentation dated November 2010

Exhibit 99.1

Investor Presentation
November 2010

Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the federal securities laws. Statements regarding future events or developments, our future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements with the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on our results of operations or financial condition. Such risks, uncertainties and other factors include, among other things: the possibility that the expected synergies, efficiencies and cost savings of the merger with Eclipsys Corporation ("Eclipsys") will not be realized, or will not be realized within the expected time period; potential difficulties or delays in achieving platform and product integration and the connection and movement of data among hospitals, physicians, patients and others; the risk that the Allscripts and Eclipsys businesses will not be integrated successfully; competition within the industries in which we operate; failure to achieve certification under the Health Information Technology for Economic and Clinical Health Act could result in increased development costs, a breach of some customer obligations and could put us at a competitive disadvantage in the marketplace; the volume and timing of systems sales and installations, the length of sales cycles and the installation process and the possibility that our products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; the outcome of any legal proceeding that has been or may be instituted against us; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry, including possible regulation of our software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; the implementation and speed of acceptance of the electronic record provisions of the American Recovery and Reinvestment Act of 2009; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers and our ability to obtain, use or successfully integrate third-party licensed technology; and breach of our security by third parties. See our Annual Report on Form 10-K for the fiscal year ended May 31, 2010 and other public filings with the SEC for a further discussion of these and other risks and uncertainties applicable to our business. The statements herein speak only as of their date and we undertake no duty to update any forward-looking statement whether as a result of new information, future events or changes in expectations.

To be the most trusted provider of innovative solutions that empower all stakeholders across the healthcare continuum to deliver world-class outcomes.

Our Mission

Allscripts™

Allscripts Corporate Snapshot

Our Clients

- 180,000 Providers
- 150,000 Physician Practices
- 1,500 Hospitals
- 10,000 Post Acute Facilities
- 27,000 Clinicians In Patients' Homes Every Day

Our Company

- 5,500 Employees
- $1.2BB LTM Pro Forma Revenue
- Facilities in 24 States, Canada, India, the Middle East and The Philippines
- 1 Complete Set of Solutions

Investment Highlights

- Leading healthcare IT company with the broadest set of capabilities across every venue of care including physicians, hospitals, post-acute and homecare
- The most utilized clinical solutions enabling health care providers to fully capitalize on the $30BB federal stimulus program
- Leadership in technology and innovation uniquely positions Allscripts to aggressively compete for the $43BB healthcare IT solutions market
- A highly attractive financial profile with high recurring revenue, significant operating leverage and cost synergy opportunities and strong free cash flow
- Proven and experienced "industrial strength" management team

The Time is NOW

A National Problem > **A Market that is Ready** > **A Significant Opportunity**

A National Problem

- Quality Issues
- Medical Errors / Safety Concerns
- Rising Cost
- Significant Waste

A Market that is Ready

- $43BB Opportunity
- $30BB in Stimulus Funding
- ~15% Penetration in Physician Practices
- Rise of the Employed Physicians
- Hospitals Driving Adoption

A Significant Opportunity

We are at the *beginning* of what we expect will be the single fastest transformation of any industry in US history

Addressing the Entire Market Opportunity

Acute/Ambulatory EHR Opportunity 2010-2014 = ~$43BB



Market Segment Seeking an Integrated/Complete Solution Across Hospitals and Physician Practices > *New* Addressable Market: **Integrated**

Pre-Merger Allscripts Opportunity (Ambulatory Stand-Alone)

Pre-Merger Eclipsys Opportunity (Acute Stand-Alone)

> *Legacy* Addressable Market: **Stand-Alone**

Source: McKinsey & Company

Well positioned to aggressively compete in the $16BB (~35%) integrated market

Allscripts

Ambulatory Market Potential

Practice Size	Total # of Practices	EHR Penetration (FY09/10)
1-3 Physicians	163,000	~13%
4-9 Physician	27,000	~22%
10-25 Physicians	8,000	~33%
26+ Physicians	2,000	~50%
Total	**200,000**	**~15%**

Source: SK&A = SK&A Information Services which sells databases for sales and marketing success in healthcare industry

Increased Certainty for Widespread EHR Adoption



Source: National Center for Health Statistics

(1) ~20% estimate based on number of ambulatory physicians; penetration as a percentage of number of physician practices is ~11%

(2) Hospitals >200 beds

Allscripts: Competitive Differentiation

One Network.

The largest connected network in the nation… and in your community.

- The Largest Network with a Client Base of 180,000 Physicians, 1,500 Hospitals and 10,000 Post Acute Care Providers
- The Unique Ability to Truly Connect a Community

One Platform.

Open, flexible, and innovative to help you connect inside and outside your organization.

- Comprehensive, Integrated Solutions for all Settings
- Rapid Implementation Approach to Attain "Meaningful Use"
- A Track Record of Innovation with a 'Future State' Clinical/Financial Informatics Capability
- Common Microsoft platform and a shared 'open architecture' approach, simplifying the connection to third-party applications across every care setting

One Patient.

A complete portfolio that delivers a single patient record across your community.

- One Patient Record Across an Organization and the Community –One Source of Truth

One Network: The Largest Community in the Nation



Hospitals

Physician Practices

Post Acute Facilities & Agencies

- **The 'Hub':** Over 1,500 Hospitals including 40% of "America's Best Hospitals" as Clients
- **The 'Spokes':** Over 180,000 MDs and 10,000 Post Acute Care Organizations are Connected to other Practices, Patients, Pharmacies, Payors, Clinical Labs and Hospitals

Allscripts

One Platform: A Complete, Integrated Solutions Portfolio



One Patient: Critical Patient Data Flows Freely



Proven Management Team

Executive	Position	Experience
Glen Tullman	CEO	30+ Yrs
Phil Pead	Chairman	30+ Yrs
Lee Shapiro	President	30+ Yrs
Eileen McPartland	COO	25+ Yrs
Bill Davis	CFO	19+ Yrs
Steve Lalonde	SVP Sales	20+ Yrs
Laurie McGraw	Chief Client Officer	20+ Yrs
John Gomez	President, Product Strategy & Development	25+ Yrs
Diane Adams	EVP, Culture and Talent	20+ Yrs

Management team with a track record of operational execution, strong financial performance, integrating acquisitions and driving shareholder value

Financial Highlights

Significant Growth

- Third quarter 2010 non-GAAP revenue of $329MM, up 12%
- Consolidated third quarter 2010 bookings of $216MM
- Third quarter 2010 non-GAAP net income of $37MM, up 21%
- ARRA stimulus program creates long-tailed demand curve

Revenue Visibility

- Backlog of $2.6BB on 9/30/2010
- High recurring revenue model
- Investments (e.g., READY, Upgrade Enablement Center, Sunrise 5.5, Helios) accelerate implementations
- Industry leading footprint—large, diverse client base

Operating Leverage

- Annualized R&D investments of ~$154MM as of the third quarter 2010, or approximately 12% of non-GAAP revenue
- Significant benefits from Project DRIVE initiatives, merger-related cost synergies
- Allscripts Distribution Network
- Strong free cash flow

Note: Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP financial measures. Information also available at http://investor.allscripts.com

Historical Consolidated Performance

Non-GAAP Revenue
CY 2009: $1,188MM



Non-GAAP Revenue
9 Months 2010: $963MM



Combined Non-GAAP Net Income ($millions)

Note: Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP financial measures. Information also available at http://investor.allscripts.com

Significant Key Cost Synergies

Key Cost Synergy Drivers

- Duplicate management structure
- Duplicate public company costs
- Duplicate backend office and system integration
- Marketing

Projected Cost Synergies Over Three Years



Revenue Synergy Opportunity of $1.25BB

ECLIPSYS

Sell Eclipsys Solutions to Allscripts Acute Care Base

Sunrise Clinical Manager, Patient Flow, EPSi

ALLSCRIPTS

Sell Allscripts Solutions to Eclipsys Acute Care Base

Care Management, Emergency Department, Homecare, Ambulatory Solutions

Incremental Revenue Opportunity				Total
~$430MM	+	**~$820MM**	=	**~$1,250MM**

$16BB Integrated Market Provides Additional Opportunity

Non-GAAP Financial Outlook (1)

($ in millions; except per share amounts)

	Q4 2010	CY 2010	CY 2011	2010 to 2011 Change
Non-GAAP Revenue	$332 - $337	$1,295 - $1,300	$1,425 - $1,450	10 - 12%
Non-GAAP Operating Margin	19%	19%	21%	–
Non-GAAP Net Income	$34 - $36	$142 - $144	$167 - $176	18 - 24%
Non-GAAP Diluted EPS	$0.18 - $0.19	$0.73 - $0.74	$0.85 - $0.89	16 - 22%

(1) Guidance provided by the company in a press release on November 8, 2010

Note: Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP financial measures. Information also available at http://investor.allscripts.com

Strong Free Cash Flow Generation

Capitalization	Actual 9/30/2010
Cash and Marketable Securities	$120
Revolver ($250mm)	60
Term Loan	470
Total Debt	**$530**
Equity	1,369
Total Capitalization	**$1,899**
Credit Statistics	
LTM EBITDA[(1)]	$293
Total Debt / LTM EBITDA[(1)]	1.8x
Debt / Capitalization	27.9%

- Reduced debt by $40MM since merger closed
- Required principal payments over next 12 months total $23.5MM
- Borrowing costs currently <4% with approximately 60% at a fixed rate

1 EBITDA is calculated as net income plus income tax expense, interest expense, stock-based compensation expense, depreciation & amortization, deferred revenue adjustments, certain one-time and transaction-related expenses, and non-recurring losses on the sale of investments minus non-recurring gains on the sale of assets.

Note: Please see reconciliation and footnotes in appendix to this presentation regarding non-GAAP financial measures. Information also available at http://investor.allscripts.com

One Network.

One Platform.

One Patient.

Allscripts™

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue and net income reconciliation for the three months ended September 30, 2010 and three months ended August 31, 2009 (Allscripts) and September 30, 2009 (Eclipsys).

	Three Months Ended 9/30/10				Three Months Ended 8/31/09	Three Months Ended 9/30/09	Q3 2009
	Allscripts	Eclipsys	Additional Int Exp (a)	Non-GAAP	Allscripts	Eclipsys	Non-GAAP
Total revenue, as reported	$191.2	$51.2	$0.0	$242.4	$164.9	$125.5	$290.4
Deferred revenue adjustment	0.5	6.7	0.0	7.2	2.6	0.6	3.2
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	79.5	0.0	79.5	0.0	0.0	0.0
Total non-GAAP revenue	$191.7	$137.4	$0.0	$329.1	$167.5	$126.1	$293.6
Net income, as reported	$5.4	($4.0)	$0.0	$1.4	$12.9	$3.9	$16.8
Deferred revenue adjustment	0.3	4.0	0.0	4.3	1.5	0.3	1.8
Acquisition-related amortization	3.4	3.0	0.0	6.4	3.5	1.9	5.4
Stock-based compensation expense	4.0	0.0	0.0	4.0	2.0	2.5	4.5
Transaction-related expense (b)	16.0	5.5	(1.9)	19.6	2.4	0.0	2.4
Restructuring	0.0	0.0	0.0	0.0	0.0	0.7	0.7
ARS Sales	0.0	0.0	0.0	0.0	0.0	0.7	0.7
Tax rate alignment	(1.6)	(0.2)	0.0	(1.8)	(0.1)	0.0	(0.1)
Tax related items	0.0	0.0	0.0	0.0	0.0	(1.7)	(1.7)
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	2.9	0.0	2.9	0.0	0.0	0.0
Non-GAAP net income	$27.5	$11.2	($1.9)	$36.8	$22.2	$8.3	$30.5

(a) For illustrative purposes, legacy Allscriptsresults for the three months ended September 30, 2010 exclude interest expense of approximately $3 million pretax, or $1.9 million on an after-tax basis attributable to the 2010 share repurchase. This expense is netted out of non-GAAP adjustments for purposes of calculating non-GAAP net income for the combined company.

(b) Various historical transaction related expenses including severance, consulting, legal, incremental interest associated with the 2010 share repurchase and other expenses.

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue and net income reconciliation for the nine months ended September 30, 2010.

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - 2010 Financial Information
(In millions, except per-share amounts)
(unaudited)

2010 Actual Results By Quarter

	Three Months Ended			Three Months Ended									
	2/28/10	**3/31/10**	**Q1 2010**	**5/31/10**	**6/30/10**	**Q2 2010**	**Three Months Ended 9/30/10**			**Q3 2010**	**Nine Months Ended 9/30/2010**		
	Allscripts	**Eclipsys**	**Non-GAAP**	**Allscripts**	**Eclipsys**	**Non-GAAP**	**Allscripts**	**Eclipsys**	**Int Exp(a)**	**Non-GAAP**	**Allscripts**	**Eclipsys**	**Non-GAAP**
Total revenue, as reported	$179.9	$128.4	$308.3	$190.3	$134.4	$324.7	$191.2	$51.2	$0.0	$242.4	$561.4	$314.0	$633.0
Deferred revenue adjustment	0.5	0.0	0.5	0.6	0.0	0.6	0.5	6.7	0.0	7.2	1.6	6.7	1.1
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	79.5	0.0	79.5	0.0	79.5	0.0
Total non-GAAP revenue	$180.4	$128.4	$308.8	$190.9	$134.4	$325.3	$191.7	$137.4	$0.0	$329.1	$563.0	$400.2	$963.2
										Percentages	**58%**	**42%**	**100%**
Net income, as reported	$18.5	$5.4	$23.9	$15.7	$1.6	$17.3	$5.4	($4.0)	$0.0	$1.4	$39.6	$3.0	$41.2
Deferred revenue adjustment	0.3	0.0	0.3	0.4	0.0	0.4	0.3	4.0	0.0	4.3	1.0	4.0	0.7
Acquisition-related amortization	3.5	1.9	5.4	3.5	1.8	5.3	3.4	3.0	0.0	6.4	10.4	6.7	10.7
Stock-based compensation expense	2.6	3.4	6.0	1.7	2.9	4.6	4.0	0.0	0.0	4.0	8.3	6.3	10.6
Transaction-related expense	0.0	0.0	0.0	5.7	2.0	7.7	16.0	5.5	(1.9)	19.6	21.7	7.5	5.8
ARS Sales	0.0	0.0	0.0	0.0	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.9	0.9
Tax rate alignment	0.7	0.0	0.7	(0.5)	0.0	(0.5)	(1.6)	(0.2)	0.0	(1.8)	-1.4	-0.2	0.2
Eclipsys results pre-merger period (7/1/10-8/23/10)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	2.9	0.0	2.9	0.0
Non-GAAP net income	$25.6	$10.7	$36.3	$26.5	$9.2	$35.7	$27.5	$11.2	($1.9)	$36.8	$79.6	$31.2	$108.8

(a) For illustrative purposes, legacy Allscriptsresults for the three months ended September 30, 2010 exclude interest expense of approximately $3 million pretax, or $1.9 million on an after-tax basis attributable to the 2010 share repurchase.

This expense is netted out of non-GAAP adjustments for purposes of calculating non-GAAP net income for the combined company.

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP net income reconciliation for the nine months ended August 31, 2009 (Allscripts) and September 30, 2009 (Eclipsys).

Allscripts Healthcare Solutions, Inc.
Non-GAAP Financial Information - 2009 Financial Information
(In millions, except per-share amounts)
(Unaudited)

2009 Actual Results By Quarter

	Three Months Ended			Three Months Ended			Three Months Ended			Nine Months Ended		
	2/28/09	3/31/09	Q1 2009	5/31/09	6/30/09	Q2 2009	8/31/09	9/30/09	Q3 2009	8/31/09	9/30/09	Q3 2009
	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP	Allscripts	Eclipsys	Non-GAAP
Net income, as reported	$13.3	($0.9)	$12.4	$13.4	($4.1)	$9.3	$12.9	$3.9	$16.8	$39.6	($1.1)	$38.5
Deferred revenue adjustment	1.9	1.0	2.9	1.5	1.8	3.3	1.5	0.3	1.8	4.9	3.1	8.0
Acquisition-related amortization	3.7	2.2	5.9	3.2	1.7	4.9	3.5	1.9	5.4	10.4	5.8	16.2
Stock-based compensation expense	1.3	3.5	4.8	1.4	4.1	5.5	2.0	2.5	4.5	4.7	10.1	14.8
Transaction-related expense	2.1	0.0	2.1	4.1	0.0	4.1	2.4	0.0	2.4	8.6	0.0	8.6
Restructuring	0.0	3.7	3.7	0.0	1.6	1.6	0.0	0.7	0.7	0.0	6.0	6.0
ARS Sales	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.0	0.7	0.7
Tax rate alignment	0.0	0.0	0.0	0.0	0.0	0.0	(0.1)	0.0	(0.1)	(0.1)	0.0	(0.1)
Tax related items	0.0	0.0	0.0	0.0	3.7	3.7	0.0	(1.7)	(1.7)	0.0	2.0	2.0
Elimination of prepackaged medications	(0.6)	0.0	(0.6)	(0.1)	0.0	(0.1)	0.0	0.0	0.0	(0.7)	0.0	(0.7)
Non-GAAP net income	$21.7	$9.5	$31.2	$23.5	$8.8	$32.3	$22.2	$8.3	$30.5	$67.4	$26.6	$94.0

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP revenue reconciliation for the twelve months ended November 30, 2009(Allscripts) and twelve months ended December 31, 2009 (Eclipsys).

	Allscripts	Eclipsys	Non-GAAP Combined
	Twelve Months Ended		
	November 30, 2009	December 31, 2009	
Total revenue, as reported	661.1	519.1	1,180.2
Deferred revenue adjustment	9.7	8.0	17.7
Elimination of prepackaged medications	(9.7)		(9.7)
Total non-GAAP revenue	661.1	527.1	1,188.2

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP net income reconciliation for the twelve months ended November 30, 2008 (Allscripts) and twelve months ended December 31, 2008 (Eclipsys).

	Allscripts	Eclipsys	Non-GAAP Combined
	Twelve Months Ended		
	November 30, 2008	December 31, 2008	
Net income, as reported	20.3	99.5	119.8
Deferred revenue adjustment	1.2	-	1.2
Acquisition-related amortization	9.4	4.8	14.2
Stock-based compensation expense	4.8	17.3	22.1
Transaction-related expense	22.7	-	22.7
AHS net income pre-Misys Healthcare merger	8.7	-	8.7
Professional services reorganization	-	1.4	1.4
Elimination of prepackaged medications	(1.9)	-	(1.9)
Non-recurring items	-	0.8	0.8
Valuation allowance	-	(80.0)	(80.0)
Headquarters Relocation	-	3.0	3.0
Derivative Litigation	-	1.3	1.3
Gain on sale of assets	-	(3.2)	(3.2)
In-process R&D charge	-	0.9	0.9
Tax related items	(0.9)	(4.0)	(4.9)
Total non-GAAP net income	64.3	41.6	105.9

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP net income reconciliation for the twelve months ended November 30, 2009 (Allscripts) and twelve months ended December 31, 2009 (Eclipsys).

	Allscripts	Eclipsys	Non-GAAP Combined
	Twelve Months Ended		
	November 30, 2009	December 31, 2009	
Net income, as reported	55.4	2.7	58.1
Deferred revenue adjustment	5.8	4.2	10.0
Acquisition-related amortization	13.9	7.7	21.6
Stock-based compensation expense	7.4	12.4	19.8
Transaction-related expense	9.4	-	9.4
Restructuring	-	6.0	6.0
ARS sales	-	0.7	0.7
Elimination of prepackaged medications	(0.7)	-	(0.7)
Tax related items	-	2.0	2.0
Tax rate alignment	0.3	0.7	1.0
Total non-GAAP net income	91.5	36.4	127.9

Appendix: Non-GAAP Reconciliation

- GAAP – non-GAAP EBITDA reconciliation for the 12 months ended September 30, 2010.

	Allscripts 9 mths ended 5/31/2010	Eclipsys 9 mths ended 6/31/2010	Allscripts 3 mths ended 9/30/2010	LTM EBITDA 8/31/2010
Net income, as reported	$49,938	$10,858	$1,373	$62,169
Income tax expense	32,611	11,252	(5,879)	37,984
Stock-based compensation expense	11,523	10,789	6,692	29,004
Depreciation & amortization	27,652	39,574	17,145	84,371
Interest expense	1,308	1,158	3,069	5,535
Transaction related/restructuring expenses	10,551	3,449	33,166	47,166
Deferred revenue adjustment	2,465	1,780	7,152	11,397
Gain on Sale of Assets	-	(503)	-	(503)
Loss on sale of investments/ARS	-	1,666	-	1,666
Eclipsys EBITDA results pre-merger period (7/1/10-8/23/10)	-	-	13,910	13,910
EBITDA	$136,048	$80,023	$76,629	$292,700

Footnotes Regarding Financial Guidance

Allscripts non-GAAP guidance for the fourth quarter of calendar 2010 assumes the following adjustments to approximately $314.0 million in GAAP revenue: an add-back of approximately $21.0 million pretax, in deferred revenue adjustments. Non-GAAP guidance for the fourth quarter of calendar 2010 assumes the following adjustments to GAAP operating and net income: add-backs of approximately $18.0 million of acquisition-related amortization; approximately $6.0 million in stock-based compensation expense; approximately $21.0 million in deferred revenue adjustments; all on a pre-tax basis. Allscripts fourth quarter 2010 non-GAAP net income and diluted earnings per share guidance assumes a 39% tax rate.

Allscripts non-GAAP guidance for calendar 2010 contemplates reported results for Allscripts from December 1, 2009 through May 31, 2010 and July 1, 2010 through December 31, 2010 and the twelve months ended December 31, 2010 for Eclipsys. Allscripts non-GAAP guidance for calendar 2010 assumes the following adjustments to approximately $1,267.0 million GAAP revenue: an add-back of approximately $29.0 million in deferred revenue adjustments, pretax. Non-GAAP guidance for calendar 2010 assumes the following adjustments to GAAP operating and net income: approximately $46.0 million of acquisition-related amortization; approximately $28.0 million in stock-based compensation expense; approximately $29.0 million in deferred revenue adjustments; all on a pre-tax basis. Allscripts 2010 non-GAAP net income and diluted earnings per share guidance assumes a 39% tax rate.

Allscripts non-GAAP guidance for calendar 2011 assumes the following adjustments to approximately $1,418.0 million in GAAP revenue: approximately $20.0 million, pre-tax in deferred revenue adjustments. Non-GAAP guidance for calendar 2011 assumes the following adjustments to GAAP operating and net income: approximately $70.0 million of acquisition-related amortization; approximately $19.0 million in stock-based compensation expense; approximately $20.0 million in deferred revenue adjustments; all on a pre-tax basis. Allscripts 2011 non-GAAP net income and diluted earnings per share guidance assumes a 38.0%-39.5% tax rate.

Explanation of Non-GAAP Financial Measures

Allscripts reports its financial results in accordance with generally accepted accounting principles, or GAAP. To supplement this information, Allscripts presents in this press release total non-GAAP revenue, gross profit, operating income and net income, including non-GAAP net income on a per share basis, which are non-GAAP financial measures under Section 101 of Regulation G under the Securities Exchange Act of 1934, as amended. Total non-GAAP revenue consists of GAAP revenue as reported and Eclipsys revenue for periods prior to the August 24, 2010 consummation of the 2010 Merger and adds back the acquisition related deferred revenue adjustment booked for GAAP purposes. Total non-GAAP gross profit consists of GAAP gross profit as reported and Eclipsys gross profit for periods prior to the consummation of the 2010 Merger and adds back the acquisition related deferred revenue adjustment booked for GAAP purposes. Total non-GAAP operating income consists of GAAP operating income as reported and Eclipsys operating income for periods prior to the consummation of the 2010 Merger and adds back the acquisition related deferred revenue adjustment booked for GAAP purposes and excludes acquisition-related amortization, stock-based compensation expense and transaction-related expenses. Non-GAAP net income consists of GAAP net income as reported and includes Eclipsys net income for periods prior to the consummation of the 2010 Merger, excludes acquisition-related amortization, stock-based compensation expense and transaction-related expenses, adds back the acquisition related deferred revenue adjustment, in each case net of any related tax effects.

Management also believes that non-GAAP revenue, gross profit, operating income and net income and non-GAAP net income on a per share basis provide useful supplemental information to management and investors regarding the underlying performance of the company's business operations and facilitates comparisons of the separate 2010 pre-merger results of legacy Allscripts and legacy Eclipsys to that of the company's 2010 post-merger results. Acquisition accounting adjustments made in accordance with GAAP can make it difficult to make meaningful comparisons of the underlying operations of the business without considering the non-GAAP adjustments that we have provided and discussed herein. Management also uses this information internally for forecasting and budgeting as it believes that the measure is indicative of the company's core operating results. In addition, the company uses Non-GAAP net income to measure achievement under the company's cash incentive compensation plans. Note, however, that non-GAAP revenue, gross profit and net income and non-GAAP net income on a per share basis are performance measures only, and they do not provide any measure of the company's cash flow or liquidity. Non-GAAP financial measures are not in accordance with, or an alternative for, measures of financial performance prepared in accordance with GAAP and may be different from non-GAAP measures used by other companies. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with Allscripts results of operations as determined in accordance with GAAP. Investors and potential investors are encouraged to review the reconciliation of non-GAAP financial measures with GAAP financial measures contained within the attached condensed consolidated financial statements.